| Value | ₹190.0 Cr |
|---|
NSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,175.50
- Market cap
- ₹1,18,283 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.2×Sector 46.5×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Partnership
Zydus Lifesciences' division Zylidac Bio partnered with Prolific Machines to scale their next-generation biologics manufacturing platform for GMP production.
Zydus Lifesciences Regulatory Approval
Zydus Lifesciences received USFDA approval for its Estradiol-Levonorgestrel Transdermal System ANDA, designated as a CGT. The product is eligible for 180-day exclusivity upon first commercial marketing.
Zydus Lifesciences Board Meeting Date
Zydus Lifesciences intimated a board meeting on 4 Nov 2026 to approve unaudited Q1/H1 FY27 results. Trading window remains closed until 6 Nov 2026.
Zydus Lifesciences Other Announcement
Zydus Lifesciences Limited has been assigned an ESG rating of 71 by NSRAL for the financial year 2026. This unsolicited rating reflects the company's sustainability performance.
Zydus Lifesciences Business Update
Zydus Lifesciences presented post-hoc analysis from its EPICS-III clinical trial for Saroglitazar at ACG 2026. The drug remains under regulatory review for PBC treatment.
Zydus Lifesciences Other Announcement
Zydus Lifesciences Limited submitted the quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming share dematerialization compliance for the quarter ended September 30, 2026.
Other capacity expansion announcements
All →Goodluck India Capacity Expansion: ₹80 Cr Investment
Goodluck India's subsidiary Goodluck Defence and Aerospace approved adding Aerospace Components as a new line of business. The estimated investment is Rs 80 Crore, within a previously approved capital outlay.
- Value
- ₹80.00 Cr
Borosil Scientific Capacity Expansion: ₹70 Cr Investment
Borosil Scientific approved a Rs.70 Crore, 20 MT per day glass tubing furnace. Commercial production is expected by March 2028.
- Value
- ₹70.00 Cr
- Execution
- Commercial production expected by March 31, 2028
- borosilicate glass tubing production capacity
- 20.0 MT per day
Forbes Precision Tools and Machine Parts Capacity Expansion: ₹60 Cr Investment
Forbes Precision approved a Rs.60 Crore investment to add 10 lakh units annually within 1 to 1.5 years. Funding will combine internal accruals and debt.
- Value
- ₹60.00 Cr
- Execution
- 1 to 1.5 year
- production capacity
- 10.0 lakh units per annum
Diensten Tech Capacity Expansion
Diensten Tech's board approved incorporating a UAE subsidiary in IT consultancy, with the investment amount not yet fixed. Name, capital and incorporation date will be disclosed on completion.
- Execution
- Approximately 3 months from board approval, subject to regulatory approvals
Supreme Holdings & Hospitality (India) Capacity Expansion
Supreme Holdings approved a related-party joint development deal for a Panvel plot, pending shareholder approval. The project targets about 1 lakh sq ft saleable area.
- saleable area
- 100000.0 sq ft
Karur Vysya Bank Capacity Expansion
Karur Vysya Bank will inaugurate eight new branches on October 30, 2026, across several states. No financial amount is disclosed, so the filing reports branch expansion only.
- new branches
- 8.0 branches